Latest News and Press Releases
Want to stay updated on the latest news?
-
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical...
-
Ipsen nomme Olivia Brown au poste de Vice-Présidente Exécutive, Directrice Mondiale des Neurotoxines
PARIS, FRANCE, 12 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui la nomination d'Olivia Brown au poste de Vice-Présidente...
-
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins,...
-
Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement...
-
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of...
-
Ipsen S.A. - Etats financiers consolidés 2024 Pièce jointe Ipsen_Comptes Consolidés 2024_FR ...
-
Ipsen S.A. - 2024 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2024_EN ...
-
Croissance des ventes totales du Groupe en 2024 en hausse de 9,9%1 à taux de change constant (8,7% en données publiées), tirée par une solide performance de toutes les aires thérapeutiques, avec...
-
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2%...
-
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of...